Is mannitol safe for patients with intracerebral hemorrhages? Renal considerations
Is mannitol safe for patients with intracerebral hemorrhages? Renal considerations
复制标题
DOI：
10.1016/s0303-8467(02)00106-3
复制
发表时间：
2003-04-01
影响因子：
1.9
通讯作者：
Slowik, A
中科院分区：
文献类型：
--
作者：
Dziedzic, T;Szczudlik, A;Slowik, A
目的：甘露醇是一种广泛用于降低颅内压的药物，可导致肾功能衰竭。本研究的目的是确定甘露醇治疗脑实质出血患者的肾脏安全性。材料与方法：按照美国心脏协会指南，对51例脑出血患者进行甘露醇治疗。在甘露醇给药前以及第2、5和14天测量血清尿素和肌酐水平。结果：观察到尿素和肌酐浓度短暂升高，但没有患者出现无尿或少尿。结论：我们的研究指出，在控制渗透压的情况下甘露醇治疗是安全的，尽管应考虑控制特殊患者组（有肾功能衰竭或糖尿病史的患者）的尿素和肌酐浓度。 (C) 2002 Elsevier Science B.V. 保留所有权利。
Objectives: Mannitol, a drug widely used to decrease intracranial pressure, can cause renal failure. The goal of this study is to determine the renal safety of mannitol therapy in patients with intraparenchymal hemorrhages. Material and Methods: 51 patients with intracerebral hemorrhages were treated with mannitol according to guideline of American Heart Association. Serum urea and creatinine levels were measured before mannitol administration and on the 2nd, 5th and 14th day. Results: Transient elevation of urea and creatinine concentration was noticed, however, none of patients developed anuria or oliguria. Conclusions: Our study points out safety of mannitol therapy under control of osmolality, although control of urea and creatinine concentrations in special group of patients (persons with history of renal failure or diabetes) should be considered. (C) 2002 Elsevier Science B.V. All rights reserved.